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Abstract
Background: We previously reported that cynomolgus monkey (CM) TRIM5a could restrict human
immunodeficiency virus type 2 (HIV-2) strains carrying a proline at the 120
th position of the capsid protein (CA), but
it failed to restrict those with a glutamine or an alanine. In contrast, rhesus monkey (Rh) TRIM5a could restrict all
HIV-2 strains tested but not simian immunodeficiency virus isolated from macaque (SIVmac), despite its genetic
similarity to HIV-2.
Results: We attempted to identify the viral determinant of SIVmac evasion from Rh TRIM5a-mediated restriction
using chimeric viruses formed between SIVmac239 and HIV-2 GH123 strains. Consistent with a previous study,
chimeric viruses carrying the loop between a-helices 4 and 5 (L4/5) (from the 82
nd to 99
th amino acid residues) of
HIV-2 CA were efficiently restricted by Rh TRIM5a. However, the corresponding loop of SIVmac239 CA alone (from
the 81
st to 97
th amino acid residues) was not sufficient to evade Rh TRIM5a restriction in the HIV-2 background. A
single glutamine-to-proline substitution at the 118
th amino acid of SIVmac239 CA, corresponding to the 120
th
amino acid of HIV-2 GH123, also increased susceptibility to Rh TRIM5a, indicating that glutamine at the 118
th of
SIVmac239 CA is necessary to evade Rh TRIM5a. In addition, the N-terminal portion (from the 5
th to 12
th amino
acid residues) and the 107
th and 109
th amino acid residues in a-helix 6 of SIVmac CA are necessary for complete
evasion from Rh TRIM5a-mediated restriction. A three-dimensional model of hexameric GH123 CA showed that
these multiple regions are located on the CA surface, suggesting their direct interaction with TRIM5a.
Conclusion: We found that multiple regions of the SIVmac CA are necessary for complete evasion from Rh
TRIM5a restriction.
Background
The host range of human immunodeficiency virus type
1 (HIV-1) is very narrow, being limited to humans and
chimpanzees [1]. HIV-1 fails to replicate in activated
CD4-positive T lymphocytes obtained from Old World
monkeys (OWM) such as rhesus (Rh) [2,3] and cyno-
molgus (CM) monkeys [4,5]. Simian immunodeficiency
virus (SIV) isolated from sooty mangabey (SIVsm) and
SIV isolated from African green monkey (SIVagm) repli-
cate in their natural hosts [6]. SIV isolated from a
macaque monkey (SIVmac) evolved from SIVsm in cap-
tive macaques, and replicates efficiently in Rh [2,3] and
CM [4,5] monkeys. Human immunodeficiency virus
type 2 (HIV-2) is assumed to have originated from
SIVsm as the result of zoonotic events involving mon-
keys and humans [7]. Previous studies have shown that
HIV-2 strains vary widely in their ability to grow in cells
of OWM such as baboon, and Rh and CM monkeys
[8-12].
In 2004, the screening of a Rh cDNA library identified
TRIM5a as a factor that confers resistance to HIV-1
infection [13]. Both Rh and CM TRIM5a proteins
restrict HIV-1 infection but fail to restrict SIVmac
[13,14]. In contrast, human TRIM5a is almost powerless
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restricts N-tropic murine leukemia viruses (N-MLV)
and equine infectious anemia virus [15-17].
TRIM5a is a member of the tripartite motif (TRIM)
family of proteins, and consists of RING, B-box 2,
coiled-coil, and SPRY (B30.2) domains [18]. Proteins
with RING domains possess E3 ubiquitin ligase activity
[19]; therefore, TRIM5a was thought to restrict HIV-1
by proteasome-dependent pathways. However, protea-
some inhibitors do not affect TRIM5a-mediated HIV-1
restriction, even though HIV-1 late reverse transcribed
products are generated normally [20-22]. TRIM5a is
thus supposed to use both proteasome-dependent and
-independent pathways to restrict HIV-1.
The intact B-box 2 domain is also required for
TRIM5a-mediated antiviral activity, since TRIM5a
restrictive activity is diminished by several amino acid
substitutions in the B-box 2 domain [23,24]. TRIM5a
has been shown to form a dimer [25,26], while the B-
box 2 domain mediates higher-order self-association of
Rh TRIM5a oligomers [27,28]. The coiled-coil domain
of TRIM5a is important for the formation of homo-oli-
gomers [29], and the homo-oligomerization of TRIM5a
i se s s e n t i a lf o ra n t i v i r a la ctivity [30,31]. The SPRY
domain is specific for an a-isoform among at least three
splicing variants transcribed from the TRIM5 gene.
Soon after the identification of TRIM5a as a restriction
factor of Rh, several studies found that differences in
the amino acid sequences of the TRIM5a SPRY domain
of different monkey species affect the species-specific
restriction of retrovirus infection [14,32-39]. Studies on
human and Rh recombinant TRIM5ash a v es h o w nt h a t
the determinant of species-specific restriction against
HIV-1 infection resides in variable region 1 (V1) of the
SPRY domain [32,33]. In the case of HIV-2 infection,
we previously found that three amino acid residues of
TFP at the 339
th to 341
st positions of Rh TRIM5a V1
are indispensable for restricting particular HIV-2 strains
that are still resistant to CM TRIM5a [34].
The SPRY domain is thus thought to recognize viral
cores. Biochemical studies have shown that TRIM5a
associates with CA in detergent-stripped N-MLV virions
[40] or with an artificially constituted HIV-1 core struc-
ture composed of the capsid-nucleocapsid (CA-NC)
fusion protein in a SPRY domain-dependent manner
[41]. Ylinen et al. mapped one of the determinants of
Rh TRIM5a sensitivity to a loop between a-helices 4
and 5 (L4/5) of HIV-2 [42]. In the present study, we
found that the 120
th amino acid of HIV-2 CA, which is
the determinant of CM TRIM5a sensitivity, also contri-
butes to Rh TRIM5a susceptibility. Furthermore, studies
on chimeric viruses between Rh TRIM5a-sensitive HIV-
2 and -resistant SIVmac revealed that multiple regions
in the N-terminal half of SIVmac CA including L4/5
contribute to the escape of SIVmac from Rh TRIM5a.
Methods
DNA constructs
The HIV-2 derivatives were constructed on a back-
ground of infectious molecular clone GH123 [43]. Con-
struction of GH123/Q, the mutant GH123 possessing Q
at the 120
th position of CA protein, and SIVmac239/P,
the mutant SIVmac239 possessing P at the 118
th posi-
tion of CA, were described previously [44]. The CA L4/
5 of GH123 or GH123/Q was replaced with the corre-
sponding segments of SIVmac239 CA using site-directed
mutagenesis with the PCR-mediated overlap primer
extension method [45], and the resultant constructs
were designated GH123/CypS or GH123/CypS 120Q,
respectively. The GH123 derivative with L4/5 of SIV-
mac239, Q at the 120
th, and A at the 179
th position of
CA (GH123/CypS 120Q 179A) was generated by site-
directed mutagenesis on a background of GH123/CypS
120Q.
Chimeric GH123 containing the whole region of SIV-
mac239 CA (GH/SCA) was generated by site-directed
mutagenesis. Restriction enzyme sites NgoM IV and Xho
I, located in the LTR and p6 cording region, respec-
tively, were used for DNA recombination. To obtain the
NgoMI V - Xho I fragment containing the CA region, we
performed four successive PCR reactions using GH123
and SIVmac239 as templates. The primers used in these
reactions were GH114F (5’-TTGGCCGGCACTGG-3’),
SCA1For (5’-CCAGTACAACAAATAGG-3’), SCA1 Rev
(5’-CCTATTTGTTGTACTGG-3’), SCA2 For (5’-
GCTAGATTAATGGCCGAAGCCCTG-3’), SCA2 Rev
(5’-CAGGGCTTCGGCCATTAATCTAGC-3’), and
2082R (5’-GACAGAGGACTTGCTGCAC-3’).
The first PCR reaction used GH123 as a template and
GH114F and GHSCA1 Rev as primers, the second used
SIVmac239 as a template and GHSCA1 For and
GHSCA2 Rev as primers, and the third used GH123 as
a template and GHSCA2 For and 2082R as primers.
The resultant 1
st,2
nd,a n d3
rd fragments were used as
templates in the fourth reaction with GH114F and
2082R as primers. The resultant NgoMI V - Xho If r a g -
ment was transferred to GH123. GH/SCA derivatives
GH/SCA N-G, GH/SCA VD, GH/SCA CypG, and GH/
SCA TE were constructed by site-directed mutagenesis
on a GH/SCA background.
To construct GH/NSCG, a GH123 derivative contain-
ing the N-terminal half (from 1
st to 120
th)o fS I V -
mac239CA, we performed three successive PCR
reactions. The first used GH/SCA as a template and
GH114F and NSCA Rev (5’-GGGATTTTGTTGTCTG-
TACATCC-3’) as primers, the second used GH123 as a
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CAAAATCCC-3’) and 2082R as primers. The resultant
1
st and 2
nd fragments were used as templates in the
third reaction with GH114F and 2082R as primers. The
resultant NgoMI V - Xho I fragment was transferred to
GH123. The GH/NSCG derivative GH/GSG was con-
structed by site-directed mutagenesis on a GH/NSCG
background.
Cells
The 293T (human kidney) and FRhK4 (Rh kidney;
American Type Culture Collection, Manassas, VA) were
cultured in Dulbecco’s modified Eagle medium supple-
mented with 10% heat-inactivated fetal bovine serum
(FBS). MT4, a human CD4 positive T cell line immorta-
lized by human T cell leukemia virus type 1 [46], was
maintained in RPMI 1640 medium containing 10% FBS.
Viral propagation
Virus stocks were prepared by transfection of 293T cells
with HIV-2 GH123 derivatives using the calcium phos-
phate co-precipitation method. Viral titers were mea-
sured with the p27 RETROtek antigen ELISA kit
(ZeptoMetrix, Buffalo, NY).
Recombinant Sendai virus (SeV) carrying Rh, CM, or
CM SPRY(-) TRIM5a was described previously [14,34].
Green fluorescence protein (GFP) expressing HIV-1 car-
rying SIVmac239 L4/5 (HIV-1-L4/5-GFP) was prepared
as described previously [47].
Viral infection
MT4 cells (2 × 10
5) were infected with SeV expressing
each of the TRIM5as, at a multiplicity of infection
(MOI) of 10 plaque-forming units (pfu) per cell and
incubated at 37°C for 9 h. Cells were then superinfected
with 20 ng of p25 of HIV-2 GH123 or derivatives, or 20
ng of p27 of SIVmac239 or derivatives. Culture superna-
tants were collected periodically, and the levels of p25 or
p27 were measured with the RETROtek antigen ELISA
kit.
Particle purification and Western blot analysis
Culture supernatant of 293T cells transfected with plas-
mids encoding HIV-1 NL43 and HIV-2 GH123 deriva-
tives was clarified using low-speed centrifugation. The
resultant supernatants were layered onto a cushion of
20% sucrose (made in PBS) and centrifuged at 35,000
rpm for 2 h in a Beckman SW41 rotor. After centrifuga-
tion, the virion pellets were resuspended in PBS and
applied to sodium dodecyl sulfate-polyacrylamide gel
electrophoresis (SDS-PAGE). Virion-associated proteins
were transferred to a PVDF membrane. CAs and cyclo-
philin A (CypA) were visualized with the serum from
SIV-infected monkeys or the anti-CypA antibody (Affi-
nity BioReagents, Golden, CO), respectively.
Saturation assay
HIV-2 or SIVmac derivative particles were prepared by
co-transfection of the relevant plasmids with one encod-
ing vesicular stomatitis virus glycoprotein (VSV-G) into
293T cells, and culture supernatants were collected two
days after transfection. One day before infection, FRhK-
4 cells were plated at a density of 2 × 10
4 cells per well
in a 24-well plate. Prior to GFP virus infection, the cells
were pretreated for 2 h with 800 ng of p25 of each of
HIV-2 or SIVmac derivatives pseudotyped with VSV-G.
Immediately after pretreatment, cells were washed and
infected with 10 ng of p24 of the HIV-1-L4/5-GFP
virus. Then, 2 h after infection, the inoculated GFP
viruses were washed and the cells cultivated in fresh
media. Two days after infection, GFP-positive cells were
counted with a flow cytometer.
Molecular modeling of hexameric HIV-2 CA
The crystal structures of the HIV-2 CA N-terminal
domain at a resolution of 1.25Å [PDB: 2WLV] [48], HIV-
1 CA C-terminal domain at a resolution of 1.70Å (PDB
code: 1A8O) [49], and hexameric HIV-1 CA at a resolu-
tion of 1.90Å [PDB:3H47] [50] were taken from the
RCSB Protein Data Bank [51]. Three-dimensional (3-D)
models of monomeric HIV-2 CA were constructed by
the homology modeling technique using ‘MOE-Align’
and ‘MOE-Homology’ in the Molecular Operating Envir-
onment (MOE) version 2008.1002 (Chemical Computing
Group Inc., Quebec, Canada) as described [44,52]. We
obtained 25 intermediate models per one homology
modeling in MOE, and selected those 3-D models which
were intermediate with best scores according to the gen-
eralized Born/volume integral methodology [53]. The
final 3-D models were thermodynamically optimized by
energy minimization using an AMBER99 force field [54]
combined with the generalized Born model of aqueous
solvation implemented in MOE [55]. Physically unaccep-
table local structures of the optimized 3-D models were
further refined on the basis of evaluation by the Rama-
chandran plot using MOE. The structures of hexameric
HIV-2 CA were generated from the monomeric struc-
t u r e sb yM O Eo nt h eb a s i so ft h ea s s e m b l yi n f o r m a t i o n
of hexameric HIV-1 CA crystal structures [50].
Results
The L4/5 loop of SIVmac239 CA and Q and A at the 120
th
and 179
th positions of CA are not sufficient for HIV-2 to
evade Rh TRIM5a-mediated restriction
Previously, we evaluated the antiviral effect of CM and
Rh TRIM5a and found that CM TRIM5a could restrict
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th position of CA,
but failed to restrict the HIV-2 GH123 mutant in which
P was replaced with Q (GH123/Q) [44] (Figure 1A). In
contrast, Rh TRIM5a could restrict both viruses [34]
(Figure 2A and 2B). Although CA of HIV-2 GH123 and
SIVmac239 share more than 87% amino acid identity
(Figure 1B), CM and Rh TRIM5as failed to restrict SIV-
mac239 (Figure 2C).
Since wild type SIVmac239 possesses Q at the 118
th
position of CA (analogous to the 120
th position of
GH123 CA), we constructed mutant SIVmac239 carry-
ing P at the 118
th position (SIVmac239/P), and found
Figure 1 Schematic representation of chimeric viral CAs. (A) White and black bars denote HIV-2 GH123 and SIVmac239 sequences,
respectively. +++, ++, +, and - denote more than 1000-fold, 100- to 1000-fold, 5- to 100-fold, and less than 5-fold suppression of viral growth,
respectively, compared with viral growth in the presence of negative control CM SPRY(-) TRIM5a on day 6. Peak titer Av. denotes average titers
in the presence of CM SPRY(-) TRIM5a on day 6 of two independent experiments. (B) Alignments of amino acid sequences of GH123 and
SIVmac239 CAs. Dots denote amino acid residues identical to one of the GH123 CA and dashes denote lack of an amino acid residue present in
GH123 CA. Boxes show the regions replaced between GH123 and SIVmac239.
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virus [44] (Figure 2D). These results indicate that Q at
the 118
th position of CA is required to evade restriction
by CM and Rh TRIM5as, although Rh TRIM5a could
restrict GH123/Q. In the case of Rh TRIM5a,i th a s
been reported that Rh TRIM5a sensitivity determinants
lie in the loop between a-helices 4 and 5 of CA protein,
equivalent to the cyclophilin A (CypA) binding loop of
HIV-1 [42]. This conclusion was made after Rh
TRIM5a restricted SIVmac-based SIV H2L in which the
L4/5 was replaced with that of HIV-2. However, when
we constructed a GH123 derivative in which L4/5 was
replaced with that of SIVmac239 (GH123/CypS), the
reciprocal virus of SIV H2L, we found that Rh TRIM5a
still restricted this virus very well (Figure 2E), indicating
that SIVmac239 L4/5 alone is not sufficient for HIV-2
to evade Rh TRIM5a restriction.
We then constructed a GH123 derivative with L4/5 of
S I V m a c 2 3 9( C y p S )a n dQa tt h e1 2 0
th position of CA
(GH123/CypS 120Q). Contrary to our expectations, Rh
TRIM5a still fully restricted this virus (Figure 2F). Since
we previously found that the amino acid change at the
179
th position of HIV-2 CA correlated with plasma viral
load in infected individuals [56], we next replaced P at
the 179
th position of GH123/CypS 120Q CA with ala-
nine (A) of SIVmac239 CA analogous to the 179
th posi-
tion of GH123 CA to generate GH123/CypS 120Q179A.
However, Rh TRIM5a also completely restricted this
virus (Figure 2G). The peak titers of GH123/CypS 120Q
and GH123/CypS 120Q179A in cells expressing Rh
TRIM5a were approximately 1000 times (+++ in Figure
1) and 300 times (++ in Figure 1), respectively, lower
than those in cells expressing CM TRIM5a lacking the
SPRY domain, CM SPRY (-) TRIM5a, a negative control
for functional TRIM5a (Figure 2F and 2G). Although
this result suggests that the 179
th amino acid slightly
contributes to evade Rh TRIM5a, it is clear that L4/5 of
SIVmac239 CA and Q at the 120
th and A at the 179
th
positions of CA were insufficient to evade Rh TRIM5a-
mediated restriction.
I nt h ec a s eo fC MT R I M 5 a, viruses carrying P at the
120
th position (GH123, GH123/CypS, and SIVmac239/
P) were restricted by CM TRIM5a, whereas all other
viruses bearing Q (GH123/Q, GH123/CypS 120Q,
GH123/CypS 120Q179A, and SIVmac239) were not
(Figures 1 and 2). These results are in good agreement
Figure 2 MT4 cells were infected with recombinant SeV expressing Rh (white circles), CM (black triangles), or CM SPRY(-) (white
squares) TRIM5a. Nine hours after infection, cells were superinfected with GH123, SIVmac239 or their derivative viruses. Culture supernatants
were separately assayed for levels of p25 from GH123 or p27 from SIVmac239. Error bars show actual fluctuations between levels of p25 or p27
in duplicate samples. A representative of two independent experiments is shown.
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th
position of HIV-2 CA alone is sufficient to evade CM
TRIM5a restriction [34,44].
The N-terminal half of SIVmac239 CA is sufficient to
evade Rh TRIM5a
To confirm that CA contains all determinants for
restriction by Rh TRIM5a, we constructed a chimeric
GH123 containing the whole region of SIVmac239 CA
(GH/SCA). This virus could grow in the presence and
absence of Rh TRIM5a (Figures 1 and 3A), clearly
excluding the possibility that some of the determinants
l i eo u t s i d et h eC A .W et h e ng e n e r a t e dac h i m e r i c
GH123 containing the N-terminal half (from the 1
st to
120
th) of SIVmac239 CA (GH/NSCG) to further narrow
down the determinant for restriction by Rh TRIM5a.
Although GH/NSCG grew to lower titers than GH/SCA,
even in the absence of Rh TRIM5a, this virus could also
grow in the presence of Rh TRIM5a (Figures 1 and 3B).
These results suggest that the N-terminal half of SIV-
mac239 CA is almost sufficient to evade Rh TRIM5a,
even though the 179
th amino acid of the C-terminal half
possessed a slight effect of restriction.
Multiple sites in the N-terminal half of SIVmac239 CA
contribute to evasion from restriction by Rh TRIM5a
I nt h eN - t e r m i n a lh a l fo fG H 1 2 3C A ,1 9a m i n oa c i d
residues differ from those of SIVmac239. We grouped
these differences into six regions as shown by boxes in
Figure 1B, and evaluated their contribution to evasion
from Rh TRIM5a by replacing each region of GH/SCA
with the corresponding region of GH123. Rh TRIM5a
completely restricted the GH/SCA derivative with the
GH123 L4/5 (CypG) (GH/SCA CypG) (Figures 1 and
3C), consistent with a previous study [42]. Rh TRIM5a
moderately restricted the GH/SCA derivative with
threonine (T) and glutamic acid (E) of GH123 at the
109
th and 111
th positions, respectively (GH/SCA TE)
(Figures 1 and 3D). These results suggest that not only
L4/5 but also the 107
th and 109
th of amino acid residues
of SIVmac239 CA (analogous to the 109
th and 111
th of
GH123 CA) contribute to evasion from restriction by
Rh TRIM5a.
Moreover, Rh TRIM5a slightly but significantly
restricted the GH/SCA derivative with the GH123 N-
terminal portion from the 5
th to 13
th amino acid resi-
dues (N-G) (GH/SCA N-G) (Figures 1 and 3E) (p <
0.05, t-test, n = 4), indicating that the SIVmac239 N-
terminal portion from 5
th to 12
th (N-S) (analogous to
N-G) is also important in evasion from Rh TRIM5a.
Consistent with this result, Rh TRIM5a which failed to
restrict GH/NSCG, couldr e s t r i c tt h eG H / N S C G
Figure 3 MT4 cells were infected with recombinant SeV
expressing Rh (white circles) or CM SPRY(-) (white squares)
TRIM5a. Nine hours after infection, cells were superinfected with
GH/SCA (A), GH/NSCG (B) or GH/SCA derivatives (C-G). Culture
supernatants were separately assayed for levels of p25. Error bars
show actual fluctuations between levels of p25 in duplicate
samples. A representative of two independent experiments is
shown.
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the other hand, Rh TRIM5a failed to restrict the GH/
SCA derivative with the valine (V) and aspartic acid (D)
of GH123 at the 27
th and 29
th positions, respectively
(GH/SCA VD) (Figures 1 and 3G). It should be noted,
however, that the growth capability of GH/SCA VD in
MT4 cells was extremely low even in the absence of
TRIM5a (Figure 3G), and further studies are necessary
to address the contribution of this region to viral sensi-
tivity to Rh TRIM5a. Similarly, the GH/SCA derivative
with glutamic acid (E) and D of GH123 at the 71
st and
75
th positions (GH/SCA ED) (Figure 1) did not grow in
MT4 cells expressing CM SPRY (-) TRIM5a,t h u s ,w e
were unable to evaluate the effect of these sites. Taken
together, we conclude that multiple sites in the N-term-
inal half of SIVmac239 CA (N-S, CypS (L4/5), and the
107
th, 109
th, and 118
th amino acid residues) contribute
to evasion from restriction by Rh TRIM5a.
We previously reported that a mutant CM TRIM5a
possessing TFP instead of Q at the 339
th position (CM
Q-TFP TRIM5a) potently restricted GH123/Q [34]. In
the present study, CM Q-TFP TRIM5a showed nearly
the same spectrum of virus restriction as Rh TRIM5a as
it completely restricted GH/SCA CypG, moderately
restricted GH/SCA TE and SIVmac239/P, and only
slightly restricted GH/SCA N-G (data not shown).
These results indicate that the virus restriction specifi-
city of Rh TRIM5a is highly dependent on the three
amino acid residues 339
th-TFP-341
st.
CypA was not incorporated into GH123, SIVmac239 or
their derivative virus particles
It has been reported that CypA was incorporated into
g r o u pMH I V - 1 ,b u tn o tH I V - 2o rS I V m a cp a r t i c l e s
[57]. To confirm that the replacement of CA between
GH123 and SIVmac239 did not augment CypA incor-
poration, we performed Western blot analysis of viral
particles from GH123, SIVmac239, and their derivatives.
A ss h o w ni nF i g u r e4( u p p e r panel), CypA proteins
were clearly detected in the particles of HIV-1 NL43 but
not in those of GH123, GH/SCA, GH/SCA CypG or
SIVmac239, although the amount of their CA proteins
was almost comparable (Figure 4, lower panel). This
result indicates that the replacement between GH123
and SIVmac239 did not augment their CypA incorpora-
tion ability.
Rh TRIM5a-resistant HIV-2 derivative virions showed
impaired saturation activity to TRIM5a in Rh cells
It is known that TRIM5a-mediated restriction of retro-
viral infection is saturated when cells are exposed to
high doses of restriction-sensitive viral particles [58-61].
To determine whether the amino acid substitutions we
generated would affect the viral ability to saturate
TRIM5a restriction, Rh FRhK4 cells were pre-treated
with equal amounts of VSV-G pseudotyped HIV-2
GH123, SIVmac239, and their derivative viruses. The
pretreated cells were then infected with VSV-G pseudo-
typed GFP expressing HIV-1 carrying SIVmac239 L4/5
(HIV-1-L4/5S-GFP) [47], since we wanted to exclude
the effects of endogenous CypA on GFP-expressing
virus in FRhK4 cells. The susceptibility of particle-trea-
ted cells to virus infection was determined by the per-
centage of GFP-positive cells.
Cells treated with HIV-2 GH123 particles showed
enhanced susceptibility to HIV-1 infection compared
with non-treated cells (Figure 5), demonstrating that
TRIM5a in FRhK4 cells was saturated by the high dose
of the particles. In contrast, cells treated with SIV-
mac239 particles showed very low levels of enhance-
ment. Cells treated with particles carrying GH123/Q
showed similar levels of enhanced susceptibility to HIV-
1 infection to those of HIV-2 GH123, while cells treated
with particles of GH123/CypS, GH123/CypS 120Q, GH/
SCA CypG or SIVmac239/P showed intermediate levels
of enhancement (Figure 5).
On the other hand, cells treated with particles carrying
GH/NSCG, GH/SCA, and GH/SCA N-G showed similar
levels of enhancement of HIV-1 susceptibility to those
of SIVmac239 (Figure 5). These results are roughly con-
sistent with our data shown in Figures 2 and 3, but
there are two differences. First, Rh TRIM5a could
Figure 4 Western blot analysis of CA and CypA in particles of
GH123, SIVmac239 and their derivatives. Viral particles from HIV-
1 NL43, HIV-2 GH123, SIVmac239, and their derivatives were purified
by ultracentrifugation through a 20% sucrose cushion. A total of 120
ng of p24 of HIV-1, p25 of HIV-2 GH123 derivatives or p27 of
SIVmac239 derivatives was applied for gel electropholesis. Cyp A
(upper panel) and CA (lower panel) were visualized by Western
blotting (WB) using an anti-CypA antibody and serum from a SIV-
infected monkey, respectively.
Kono et al. Retrovirology 2010, 7:72
http://www.retrovirology.com/content/7/1/72
Page 7 of 13completely restrict GH123/CypS and GH123/CypS
120Q (Figure 2), while particles of these viruses showed
decreased levels of enhancement compared with those
of GH123 or GH123/Q (Figure 5). Second, Rh TRIM5a
could slightly restrict GH/SCA N-G (Figure 3E), while
particles of this virus failed to saturate Rh TRIM5a (Fig-
ure 5). Although the precise reasons for these differ-
ences are unclear at present, similar differences were
previously reported in HIV-1 CA mutant constructs,
and might be due to differences in core stability among
mutant viral particles [62]. Nevertheless, our data in Fig-
ure 5 clearly indicate the importance of L4/5 (compare
GH123 with GH123/CypS, GH/SCA with GH/SCA
CypG) and other CA regions (compare GH123 with
GH/SCA CypG, SIVmac239 with SIVmac239/P) in the
viral ability to saturate TRIM5a in Rh FRhK4 cells, and
suggest that the multiple sites in the N-terminal half of
GH123 CA affect its binding to Rh TRIM5a.
Finally, we checked viral release and maturation/pro-
cessing of GH123, SIVmac239, and their derivative
viruses by a western blot for the lysate of viral producer
cells (Figure 6, upper panel) and viral particles (Figure 6,
lower panel), since viral maturation is essential for
TRIM5a recognition. CA proteins in the cells and
released viral particles were clearly detected. CAs with
SIVmac239 L4/5 showed slightly reduced mobility com-
pared with those with GH123 L4/5. Although there
were small differences in the amounts of CA among
viruses tested, there was no difference in the ratio of
intracellular CA to those in the released viral particles.
It should be also mentioned that there was no difference
in the ratio of Gag precursors to processed CA in the
viral producer cells. These results indicated that viral
release and maturation/processing of the derivative
viruses occurred normally.
Structural model of HIV-2 GH123 CA
To gain a structural insight into the mechanisms by
which Rh TRIM5a recognizes HIV-2 CA, three-dimen-
sional (3-D) models of monomeric and hexameric
HIV-2 GH123 CA were constructed using homology-
modeling based on the crystal structures of the HIV-2
CA N-terminal domain [48], HIV-1 CA C-terminal
domain [49], and the hexameric HIV-1 CA [50]. All
amino acid residues conferring sensitivity to Rh
TRIM5a restriction (N-G, CypG (L4/5), the 109
th T,
111
th E, and 120
th P) are located on the surface of CA
Figure 5 Activity of GH123, SIVmac239, and their derivatives to
saturate TRIM5a in Rh cells. (A) Rh FRhK-4 cells were pretreated
with equal amounts of VSV-G pseudotyped particles (800 ng of p25
or p27) of GH123, GH123/Q, GH123/CypS, GH123/CypS 120Q, GH/
NSCG, GH/SCA N-G, GH/SCA CypG, GH/SCA, SIVmac239 or
SIVmac239/P for 2 h. Cells were then infected with the VSV-G
pseudotyped GFP-expressing HIV-1 vector carrying SIVmac L4/5.
Data from triplicate samples (means ± SD) expressed as % GFP
positive cells subtracted with the value of mock-treated cells
(24.88%) are shown. Statistical significance of differences was
calculated using the t-test. Asterisks above bars show differences
between indicated viruses and SIVmac239. ***, P < 0.001;
**, P < 0.01; ns, not significant. The statistical significance of
differences between GH123 and GH123/CypS and that between
GH123 and GH/SCA CypG were both < 0.001.
Figure 6 Western blot analysis of lysates of viral producer cells
and viral particles. Viral proteins in the lysate of equal number of
viral producer cells (upper panel) and particle fraction of equal
volume of culture supernatant of viral producer cells (lower panel)
were visualized by WB using serum from an SIV-infected monkey.
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Page 8 of 13(Figure 7A, C and 7D), suggesting that these positions
are involved in interaction with Rh TRIM5a.O nt h e
other hand, amino acid residues that impaired viral
growth in the absence of TRIM5a (27
th V, 29
th D, 71
st
E, and 75
th D) are located on the side of CA (Figure 7A
and 7D). Although we were unable to determine the
effect of these amino acid residues on viral sensitivity to
Rh TRIM5a restriction, the structural models suggest
that these sites are buried inside multimerized CA. It is
therefore unlikely that they are involved in the direct
interaction of CA with Rh TRIM5a.
Discussion
A previous study on the recombination between HIV-2
ROD and SIVmac showed that the CA region corre-
sponding to the CypA binding loop of HIV-1 (L4/5) is
Figure 7 Three-dimensional structural models of GH123 CA. (A) Structure of the N-terminal half of CA monomer. The model was
constructed by homology-modeling using “MOE-Align” and “MOE-Homology” in the Molecular Operating Environment (MOE) as described
previously [73,74]. N-G, dark purple; the 27
thV and the 29
thD, pink; Cyp G (L4/5), orange; the 71
stE, green; the 75
thD, light purple; the 109
th T, dark
blue; the 111
th E, light blue; and the 120
th P, red. The structure of CA hexamer from the top (B and C) and side (D) is shown.
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Page 9 of 13the determinant for susceptibility to Rh TRIM5a [42]. A
subsequent study on HIV-1 and SIVagmTAN showed
that the loop between helices 6 and 7 (L6/7) also contri-
butes to Rh TRIM5a susceptibility [63]. In the present
study, we showed that the L4/5 and the 120
th amino
acids located in L6/7 were required but not sufficient
for HIV-2 to evade Rh TRIM5a-mediated restriction.
In addition to L4/5 and L6/7, we found that the N-
terminal portion (from the 5
th to 12
th amino acid
residues), and 107
th and 109
th amino acid residues in a-
helix 6 of SIVmac239 CA are required for Rh TRIM5a
evasion. The 3-D models of CA showed that the analo-
gous regions of GH123 CA are located on the surface of
the CA core structure, suggesting that these sites are
involved in the direct interaction of CA with Rh
TRIM5a. Our results are in good agreement with a pre-
vious report in which the HIV-1 derivative with an
entire CA and Vif of SIVmac239 could replicate in Rh
cells [64]. In addition, we observed that the HIV-1 deri-
vative with L4/5 and L6/7 of CA and Vif of SIVmac239
(NLScaVR6/7S) that replicates in CM cells [47] failed to
replicate in Rh cells (Kuroishi et al., unpublished data).
The growth ability of GH123 was higher than that of
SIVmac239 in SeV-infected MT4 cells, but that of many
GH123 derivatives with SIVmac239 CA sequences was
lower than that of the parental GH123 and comparable
with that of SIVmac239 (Figures 1, 2, and 3). However,
GH/SCA VD replicated very poorly and GH/SCA ED
did not replicate at all. These results were reproducible
using the viruses produced with independent plasmid
clones, after which Gag processing of these viruses
occurred normally (data not shown). As shown in Figure
7, the 27
th Va n d2 9
th Da r ei na-helix 1, and the 71
st E
and 75
th D are in a-helix 4. It is possible that the amino
acid changes at these sites are harmful for the formation
of a multimerized viral core. Supporting this notion, the
27
th Va n d7 1
st E are highly conserved among different
HIV-2 strains in the Los Alamos sequence database.
Furthermore, the 71
st Ea n d7 5
th D are located on the
lateral side of the CA hexametric structure (Figure 7D),
and thus it is possible that these amino acid residues
associate with the neighboring CA hexamer. It is thus
interesting to know the impact of such amino acid
changes on viral core formation.
It has been reported that the CypA-CA interaction
renders HIV-1 more susceptible to Rh TRIM5a restric-
tion [65-68]. We found that HIV-2 CA L4/5 corre-
sponding to the CypA binding loop of HIV-1 had the
biggest impact on Rh TRIM5a susceptibility, although
we could not detect CA-CypA binding (Figure 4). Braa-
ten et al.a l s or e p o r t e dt h a tn e i t h e rH I V - 2n o rS I V
recruits CypA into their cores, and that drugs that block
CA-CypA interaction have no effect on the titers of
these viruses [57]. CA crystal structures of human T-cell
lymphotropic virus type 1 [PDB: 1QRJ] [69] and equine
infectious anemia virus [PDB: 1EIA] [70] possess an
exposed loop directed to the surface of the CA core
structure, similar to the HIV-1 CypA binding loop,
while retroviruses such as B-tropic murine leukemia
virus [PDB: 3BP9] [71] and Jaagsiekte sheep retrovirus
[PDB: 2V4X] [72] do not. It is reasonable to assume
that this HIV-2 loop would interact with certain host
factors other than CypA, and consequently is an attrac-
tive target for TRIM5a.
The differences in the L4/5 amino acid sequence
among different strains of HIV-2, SIVmac, and SIVsmm
are shown in Figure 8. Of these, SIVmac-specific amino
acid residues are the 88
th A, 90
th-QQΔ-92
nd,a n d9 9
th S
(Figure 8 boxes). Ylinen et al. reported that SIVmac QQ
LPA, the mutant SIVmac containing HIV-2-specific
LPA instead of QQ at the 90
th to 92
nd positions, was
still not restricted by Rh TRIM5a [42], suggesting that
the 88
th and 99
th amino acids or all amino acid substitu-
tions in L4/5 between SIVmac and HIV-2 are involved
in resistance to Rh TRIM5a restriction.
We previously reported that the TFP motif in the
SPRY domain of Rh TRIM5a is important in restriction
Figure 8 Alignments of amino acid sequences of the CA L4/5
region of HIV-2, SIVmac, and SIVsmm selected from the Los
Alamos databases. Dots denote the amino acid identical to one of
the GH123 CA and dashes denote lack of an amino acid residue
that is present in GH123 and other viruses. Boxes show the site of
SIVmac-specific amino acid residues. H2A, B, and U represent HIV-2
group A, B, and U, respectively. MAC represents SIVmac, and SMM
denotes SIVsmm.
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Page 10 of 13of HIV-2 strains that are not restricted by CM TRIM5a
[34]. In the present study, we confirmed that this motif
is both necessary and sufficient to restrict various HIV-
2-SIVmac chimeras that are restricted by Rh TRIM5a.
If the TFP motif in the SPRY domain of Rh TRIM5a is
directly involved in interaction with viral CA, it is not
clear why multiple regions of SIVmac239 are necessary
for evasion from TRIM5a with a TFP motif. We pre-
v i o u s l yc o n s t r u c t e dt h e3 - Ds t r u c t u r a lm o d e lo ft h e
SPRY domain [36] using homology modeling. It would
therefore be of interest to construct a 3-D binding
model of CA and TRIM5a, and to understand how the
339
th-TFP-341
st motif of Rh TRIM5a affects recognition
of the CAs that differ at multiple positions.
Conclusion
We found that multiple regions of the SIVmac CA, not
only L4/5 and the 118
th amino acid but also the N-
terminal portion (from the 5
th to 12
th amino acid resi-
dues), and the 107
th and 109
th amino acid residues, are
necessary for complete evasion from Rh TRIM5a
restriction.
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